We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Massachusetts judge ruled that Biogen must face a False Claims Act lawsuit brought by former employees alleging the company paid healthcare providers kickbacks to prescribe Biogen’s multiple sclerosis products, including Avonex, Tecfidera and Tysabri. Read More
In a move applauded by domestic drug groups, the U.S. Trade Representative added Canada to its priority watch list of countries with lax intellectual property protections or market access barriers for drugs. Read More
Citing concerns among stakeholders including the FDA, the U.S. Pharmacopeia decided not to move forward with proposed revisions to its nomenclature for biologics. Read More
Citing a Merck in-house attorney’s dishonesty under oath, the Federal Circuit upheld a 2016 ruling that dismissed a $200 million verdict against Gilead, affirming that Merck unethically obtained the rights to two patents. Read More
The International Brotherhood of Teamsters — shareholders in McKesson — expressed skepticism about the outcome of a probe that cleared the drug company’s leadership of contributing to the opioid epidemic. Read More
In comments to the European Medicines Agency, leading drugmakers requested more clarification, simpler language and various other revisions for the International Conference on Harmonisation’s draft addendum to its E9 guidelines. Read More